PURPOSE: Adverse symptom event reporting is vital as part of clinical trials and drug labeling to ensure patient safety and inform risk-benefit decision making. The purpose of this study was to assess the reliability of adverse event reporting of different clinicians for the same patient for the same visit. METHODS: A retrospective reliability analysis was completed for a sample of 393 cancer patients (42.8% men; age 26-91, M = 62.39) from lung (n = 134), prostate (n = 113), and Ob/Gyn (n = 146) clinics. These patients were each seen by two clinicians who independently rated seven Common Terminology Criteria for Adverse Events (CTCAE) symptoms. Twenty-three percent of patients were enrolled in therapeutic clinical trials. RESULTS: The average time between rater evaluations was 68 min. Intraclass correlation coefficients were moderate for constipation (0.50), diarrhea (0.58), dyspnea (0.69), fatigue (0.50), nausea (0.52), neuropathy (0.71), and vomiting (0.46). These values demonstrated stability over follow-up visits. Two-point differences, which would likely affect treatment decisions, were most frequently seen among symptomatic patients for constipation (18%), vomiting (15%), and nausea (8%). CONCLUSION: Agreement between different clinicians when reporting adverse symptom events is moderate at best. Modification of approaches to adverse symptom reporting, such as patient self-reporting, should be considered.
PURPOSE: Adverse symptom event reporting is vital as part of clinical trials and drug labeling to ensure patient safety and inform risk-benefit decision making. The purpose of this study was to assess the reliability of adverse event reporting of different clinicians for the same patient for the same visit. METHODS: A retrospective reliability analysis was completed for a sample of 393 cancerpatients (42.8% men; age 26-91, M = 62.39) from lung (n = 134), prostate (n = 113), and Ob/Gyn (n = 146) clinics. These patients were each seen by two clinicians who independently rated seven Common Terminology Criteria for Adverse Events (CTCAE) symptoms. Twenty-three percent of patients were enrolled in therapeutic clinical trials. RESULTS: The average time between rater evaluations was 68 min. Intraclass correlation coefficients were moderate for constipation (0.50), diarrhea (0.58), dyspnea (0.69), fatigue (0.50), nausea (0.52), neuropathy (0.71), and vomiting (0.46). These values demonstrated stability over follow-up visits. Two-point differences, which would likely affect treatment decisions, were most frequently seen among symptomatic patients for constipation (18%), vomiting (15%), and nausea (8%). CONCLUSION: Agreement between different clinicians when reporting adverse symptom events is moderate at best. Modification of approaches to adverse symptom reporting, such as patient self-reporting, should be considered.
Authors: John P A Ioannidis; Stephen J W Evans; Peter C Gøtzsche; Robert T O'Neill; Douglas G Altman; Kenneth Schulz; David Moher Journal: Ann Intern Med Date: 2004-11-16 Impact factor: 25.391
Authors: Elizabeth A Hahn; David Cella; Olivier Chassany; Diane L Fairclough; Gilbert Y Wong; Ron D Hays Journal: Mayo Clin Proc Date: 2007-10 Impact factor: 7.616
Authors: Donna L Berry; Carol M Moinpour; Caroline S Jiang; Donna Pauler Ankerst; Daniel P Petrylak; Lynne V Vinson; Primo N Lara; Sharon Jones; Mary E Taplin; Patrick A Burch; Maha H A Hussain; E David Crawford Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Saul N Weingart; Tejal K Gandhi; Andrew C Seger; Diane L Seger; Joshua Borus; Elisabeth Burdick; Lucian L Leape; David W Bates Journal: Arch Intern Med Date: 2005-01-24
Authors: Deborah Watkins Bruner; Charlene J Bryan; Neil Aaronson; C Craig Blackmore; Michael Brundage; David Cella; Patricia A Ganz; Carolyn Gotay; Pamela S Hinds; Alice B Kornblith; Benjamin Movsas; Jeff Sloan; Lari Wenzel; Giles Whalen Journal: J Clin Oncol Date: 2007-11-10 Impact factor: 44.544
Authors: Jordanka Kirkova; Mellar P Davis; Declan Walsh; Eoin Tiernan; Norma O'Leary; Susan B LeGrand; Ruth L Lagman; K Mitchell Russell Journal: J Clin Oncol Date: 2006-03-20 Impact factor: 44.544
Authors: Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934
Authors: Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch Journal: JAMA Oncol Date: 2015-11 Impact factor: 31.777
Authors: Edward J Fox; Alberto Vasquez; William Grainger; Tina S Ma; Christian von Hehn; John Walsh; Jie Li; Javier Zambrano Journal: Int J MS Care Date: 2016 Jan-Feb
Authors: Donna R Rivera; Patricia A Ganz; Meghan S Weyrich; Hanna Bandos; Joy Melnikow Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: Ethan Basch; Bryce B Reeve; Sandra A Mitchell; Steven B Clauser; Lori M Minasian; Amylou C Dueck; Tito R Mendoza; Jennifer Hay; Thomas M Atkinson; Amy P Abernethy; Deborah W Bruner; Charles S Cleeland; Jeff A Sloan; Ram Chilukuri; Paul Baumgartner; Andrea Denicoff; Diane St Germain; Ann M O'Mara; Alice Chen; Joseph Kelaghan; Antonia V Bennett; Laura Sit; Lauren Rogak; Allison Barz; Diane B Paul; Deborah Schrag Journal: J Natl Cancer Inst Date: 2014-09-29 Impact factor: 13.506
Authors: Tamara P Miller; Yimei Li; Marko Kavcic; Kelly D Getz; Yuan-Shun V Huang; Lillian Sung; Todd A Alonzo; Robert Gerbing; Marla H Daves; Terzah M Horton; Michael A Pulsipher; Jessica Pollard; Rochelle Bagatell; Alix E Seif; Brian T Fisher; Selina Luger; Alan S Gamis; Peter C Adamson; Richard Aplenc Journal: Haematologica Date: 2017-06-22 Impact factor: 9.941
Authors: Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann Journal: Lancet Haematol Date: 2018-06-18 Impact factor: 18.959